Erlotinib Completed Phase 1 / 2 Trials for Cancer, Breast Treatment

IndicationsStatusPurposePhase
CompletedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT01650506Study of Erlotinib and Metformin in Triple Negative Breast Cancer
NCT00574366Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer